Le Gouill, Steven - Resultados de la búsqueda - Depósito Digital de Documentos de la UAB

Buscar colecciones:

Ordenar por:	Mostrar resultados:	Formato de visualización:

Resultados globales: 2 registros encontrados en 0.02 segundos.
Artículos, Encontrados 2 registros

Artículos	Encontrados 2 registros

12 p, 600.5 KB

A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma / Carlo-Stella, Carmelo (Humanitas Research Hospital (Itàlia)) ; Zinzani, Pier Luigi (IRCCS Azienda Ospedaliero-Universitaria di Bologna) ; Sureda, Anna (Hospital Universitari de Bellvitge) ; Araújo, Luis (Universitário de Coimbra) ; Casasnovas, Olivier (CHU Dijon Bourgogne) ; Carpio Segura, Cecilia del Carmen (Hospital Universitari Vall d'Hebron) ; Yeh, Su-Peng (China Medical University Hospital) ; Bouabdallah, Krimo (University Hospital of Bordeaux) ; Cartron, Guillaume (Centre Hospitalier Universitaire Montpellier) ; Kim, Won Seog (Samsung Medical Center) ; Cordoba, Raul (Hospital Universitario Fundación Jiménez Díaz) ; Koh, Youngil (Seoul National University Hospital) ; Re, Alessandro (ASST Spedali Civili Brescia) ; Alves, Daniela (Centro Hospitalar Universitário Lisboa Norte) ; Chamuleau, Martine (Vrije Universiteit Amsterdam) ; Le Gouill, Steven (Institut Curie) ; López Guillermo, Armando (Hospital Clínic i Provincial de Barcelona) ; Moreira, Ilídia (Portuguese Institute of Oncology of Porto) ; van der Poel, Marjolein W. M. (Maastricht University Medical Center) ; Abbadessa, Giovanni (Sanofi) ; Meng, Robin (Sanofi) ; Ji, Ran (Sanofi) ; Lépine, Lucie (Sanofi) ; Saleem, Rao (Sanofi) ; Ribrag, Vincent (Institut Gustave Roussy (Villejuif, França)) ; Universitat Autònoma de Barcelona
Patients with relapsed or refractory lymphoma have limited treatment options, requiring newer regimens. In this Phase 1/2 study (NCT03769181), we assessed the safety, efficacy, and pharmacokinetics of isatuximab (Isa, anti-CD38 antibody) in combination with cemiplimab (Cemi, anti-programmed death-1 [PD-1] receptor antibody; Isa + Cemi) in patients with classic Hodgkin lymphoma (cHL), diffuse large B-cell lymphoma (DLBCL), and peripheral T-cell lymphoma (PTCL). [...]
2022 - DOI (Digital Object Identifier)

10.1002/hon.3089
Hematological Oncology, Vol. 41 (october 2022) , p. 108-119

Registro completo -

18 p, 2.5 MB

The EHA Research Roadmap : Malignant Lymphoid Diseases / Dreyling, Martin (LMU Hospital (Alemanya)) ; André, Marc (Université Catholique de Louvain (bèlgica)) ; Gökbuget, Nicola (Goethe University (Alemanya)) ; Tilly, Hervé (Centre Henri Becquerel and Université de Rouen (França)) ; Jerkeman, Mats (Skåne University and Lund University (Suècia)) ; Gribben, John (Queen Mary University of London (Regne Unit)) ; Ferreri, Andrés (IRCCS San Raffaele Scientific Institute (Itàlia)) ; Morel, Pierre (CHU Amiens Picardie (França)) ; Stilgenbauer, Stephan (Universität Ulm (Alemanya)) ; Fox, Christopher (University of Nottingham (Regne Unit)) ; Maria Ribera, José (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Zweegman, Sonja (Amsterdam UMC (Països Baixos)) ; Aurer, Igor (University of Zagreb (Zagreb)) ; Bödör, Csaba (Semmelweis University (Hongria)) ; Burkhardt, Birgit (Pädiatrische Hämatologie und Onkologie (Alemanya)) ; Buske, Christian (University Hospital of Ulm (Alemanya)) ; Dollores Caballero, Maria (El Instituto de Investigación Biomédica de Salamanca (Salamanca, Espanya)) ; Campo, Elias (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Chapuy, Bjoern (Berlin Institute of Health (Alemanya)) ; Davies, Andrew (University of Southampton (Regne Unit)) ; de Leval, Laurence (Lausanne University Switzerland (Suïssa)) ; Doorduijn, Jeanette (University Medical Center Rotterdam the Netherlands (Països Baixos)) ; Federico, Massimo (GVM Care & Research (Itàlia)) ; Gaulard, Philippe (Hôpital Henri Mondor (França)) ; Gay, Francesca (AOU Città Della Salute e Della Scienza (Itàlia)) ; Ghia, Paolo (IRCCS Ospedale San Raffaele (Itàlia)) ; Grønbæk, Kirsten (University of Copenhagen (Dinamarca)) ; Goldschmidt, Hartmut (University Hospital Heidelberg (Alemanya)) ; Kersten, Marie-Jose (Cancer Center Amsterdam and LYMMCARE the Netherlands (Països Baixos)) ; Kiesewetter, Barbara (Medical University of Vienna (Àustria)) ; Landman-Parker, Judith (Sorbonne Université APHP/hôpital A Trousseau (França)) ; Le Gouill, Steven (Clinique du Centre Hospitalier Universitaire (CHU) de Nantes (França)) ; Lenz, Georg (Medical University Hospital Münster (Alemanya)) ; Leppä, Sirpa (Helsinki University Hospital Comprehensive Cancer Centre Finland (Finlandia)) ; López Guillermo, Armando (Hospital Clínic i Provincial de Barcelona) ; Macintyre, Elizabeth (Assistance Publique-Hôpitaux de Paris (França)) ; Mantega, Maria Victoria Mateos (Universidad de Salamanca (Salamanca, Espanya)) ; Moreau, Philippe (University Hospital Hotel-Dieu (França)) ; Moreno, Carol (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ; Nadel, Bertrand (Aix Marseille Univ (França)) ; Okosun, Jessica (Queen Mary University of London (Regne Unit)) ; Owen, Roger (St James's Institute of Oncology (Regne Unit)) ; Pospisilova, Sarka (University Hospital Brno (Txèquia)) ; Pott, Christiane (Universitätsklinikum Schleswig-Holstein (Alemanya)) ; Robak, Tadeusz (Medical University of Lodz (Polònia)) ; Spina, Michelle (National Cancer Institute (Itàlia)) ; Stamatopoulos, Kostas (Centre for Research and Technology Hellas Greece (Grècia)) ; Stary, Jan (Charles University Prague University Hospital Czech Republic (Txèquia)) ; Tarte, Karin (Immunology and Cell Therapy Lab at Rennes University Hospital (França)) ; Tedeschi, Allessandra (Niguarda Hospital Milano (Itàlia)) ; Thieblemont, Catherine (Assistance Publique-Hôpitaux de Paris (França)) ; Trappe, Ralf Ulrich (DIAKO Hospital Bremen (Alemanya)) ; Trümper, Lorenz H. (University Medicine Goettingen (Alemanya)) ; Salles, Gilles (Weill Cornell Medicine (Estats Units)) ; Universitat Autònoma de Barcelona
2022 - DOI (Digital Object Identifier)

10.1097/HS9.0000000000000726
HemaSphere, Vol. 6 (may 2022)

Registro completo -

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.